Last reviewed · How we verify

post operative analgesics

Ain Shams University · FDA-approved active Small molecule Quality 5/100

Post operative analgesics, developed by Ain Shams University, are currently marketed but lack detailed revenue figures and primary indication data. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The absence of key trial results and identified competitors poses a significant risk to assessing the drug's market performance and competitive landscape.

At a glance

Generic namepost operative analgesics
Also known aspain control drug
SponsorAin Shams University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: